David Germonpré is Investment Partner at MTIP responsible for the sourcing and execution of deals and active portfolio management.
David Germonpré is a seasoned venture capital investor and board member with a strong focus on medtech and digital health. Before joining MTIP, he invested for the Gemma Frisius Fund in spin-offs from Belgium’s KU Leuven, Europe’s most innovative university (Reuters ranking). Between 2009 and 2013 Mr. Germonpré advised the Government of Flanders on its investment vehicles. Prior to that he worked as an investment banker at Dexia Bank focusing on M&A and Equity Capital Market transactions for big corporates. Mr. Germonpré holds a Master degree in Commercial Sciences from Ghent University. In 2013 he completed an Executive MBA at the top-ranked IE Business School (Madrid, Spain).
Involvement in portfolio companies
Blueprint Genetics stands for comprehensive genetic diagnostic with quality you can see
Digital Health, Diagnostics
Quanta is the developer of advanced haemodialysis systems for use in the home and clinic.
Lumeon is the leading platform for care pathway automation